View : 956 Download: 274
FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial
- Title
- FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial
- Authors
- Kim, Jang-Young; Son, Jung-Woo; Park, Sungha; Yoo, Tea-Hyun; Kim, Yong-Jin; Ryu, Dong-Ryeol; Chin, Ho Jun
- Ewha Authors
- 류동열
- SCOPUS Author ID
- 류동열
- Issue Date
- 2017
- Journal Title
- TRIALS
- ISSN
- 1745-6215
- Citation
- TRIALS vol. 18
- Keywords
- Proteinuria; Chronic kidney disease; Hypertension; Diabetes mellitus
- Publisher
- BIOMED CENTRAL LTD
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Background: Fimasartan is the ninth angiotensin receptor blocker to be developed. However, it has not yet been evaluated for reno-protective effects in hypertensive diabetic chronic kidney disease (CKD). The target blood pressure (BP) for hypertensive diabetic CKD is also a controversial topic. This trial was designed to assess the reno-protective effects of fimasartan compared to those of losartan as a primary outcome. This study also compares the two drugs with regard to cardiovascular and renal outcomes in accordance with target systolic BP (SBP) (as secondary outcomes). Methods: This study is a prospective, phase III, randomized, double-blind, active-controlled, non-inferiority, four-parallel group, dose-titration, multicenter trial. We recruit patients with hypertensive diabetic CKD with overt proteinuria. Participants will be randomized into four groups (1: 1: 1: 1): fimasartan standard SBP control (SBP < 140 mmHg); fimasartan strict SBP control (SBP < 130 mmHg); losartan standard SBP control; and losartan strict SBP control. After 24 weeks, all individuals are treated with fimasartan for an additional 120 weeks in an open-label design, maintaining their assigned SBP control groups as randomized. The primary endpoint is the rate of change in proteinuria, which is assessed using the spot urine albumin-creatinine ratio at 24 weeks. The secondary endpoints are the cardiovascular and renal outcomes at 144 weeks compared between the strict SBP and standard SBP control groups. Discussion: The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria.
- DOI
- 10.1186/s13063-017-2375-8
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
-
FimAsartaN.pdf(896.86 kB)
Download
- Export
- RIS (EndNote)
- XLS (Excel)
- XML